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A B S T R A C T
Fascin is an actin binding and bundling protein that is not expressed in normal epithelial tissues but over-
expressed in a variety of invasive epithelial tumors. It has a critical role in cancer cell metastasis by promoting
cell migration and invasion. Here we report the crystal structures of fascin in complex with a series of novel and
potent inhibitors. Structure-based elaboration of these compounds enabled the development of a series with
nanomolar affinities for fascin, good physicochemical properties and the ability to inhibit fascin-mediated
bundling of filamentous actin. These compounds provide promising starting points for fascin-targeted anti-
metastatic therapies.
Introduction
Fascin 1 (hereafter termed fascin) is an evolutionarily conserved actin
binding protein that cross-links filamentous actin (F-actin) into tightly
packed parallel bundles driving the formation of various cell surface
protrusions, such as filopodia and invadopodia, that promote cell mi-
gration and invasion.1 It’s expression is highly restricted in adult human
tissues.2 Fascin is either absent or shows low expression in normal epi-
thelial tissues but is overexpressed in a number of cancers, with expres-
sion levels correlating with overall cancer aggressiveness and predicting
poor clinical outcome.3,4 Conversely, genetic knockdown of fascin de-
creases tumor cell invasion both in vitro and in vivo,5,6 suggesting that
fascin may be a viable target for anticancer/antimetastatic drugs. Huang
et al. have disclosed compounds which bind to fascin and inhibit actin
bundling.7–9 However, in our hands a number of these compounds bound
with modest (10–100 µM) affinity and suffered from poor solubility.
In order to identify novel fascin compounds, with favourable
properties, we undertook a surface plasmon resonance (SPR) screen
using our collection of 1050 fragments and identified 53 hits (hit rate
5%). Follow-up protein crystallography yielded a range of fragments
binding to multiple sites on the protein.
The N-phenylacetamide 1 (Fig. 1A) binds efficiently (SPR
Kd= 92 μM; ligand efficiency 0.43)11 in a buried pocket between the
first and second β-trefoil domain (Fig. 1B) and was therefore selected
for further development. Binding of compound 1 induces a hydrophobic
pocket in domain 1, mainly by displacing Trp101. In addition, domain 1
pivots by ≈15°, reorienting residues on either side of the domain in-
terface and creating a narrow channel to the protein surface (Fig. 1C
and D). The dichlorophenyl moiety of 1 fills the hydrophobic pocket,
while the acetamide engages in hydrophilic interactions with domain 2,
with its carbonyl accepting a hydrogen bond from the backbone of
Leu214 (Fig. 1E). While the completely enclosed binding site makes
compound 1 a highly efficient ligand, it hampered attempts to develop
this series.
The importance of this fragment binding site was highlighted when
we determined the crystal structure of compound 2 (Fig. 2A)
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previously identified by Huang et al. to inhibit fascin-mediated actin
bundling.12 To accommodate the larger compound 2, domain 1 un-
dergoes a more dramatic conformational change, rotating 35° around
an axis almost parallel to a line connecting the first two β-trefoil do-
mains (Fig. 2B). For the compound binding site (Fig. 2C) this almost
pure rotation results in a 6 Å ‘drop’ of domain 2 relative to domain 1, so
that the Phe216 side chain, which in the fascin·compound 1 complex
lines the channel, now extends the hydrophobic pocket (cf. Figs. 1D and
2C) where the compound’s dichlorobenzyl moiety binds. More
importantly, the conformational change opens up the channel so that it
can accommodate the rest of the compound. The pyrazolopyrimidinone
core rests on a relatively flat surface created by the salt-bridged side
chains of Glu215 and Arg217. Additionally, compound 2 accepts a
hydrogen bond from Phe216 and makes a relatively weak water-
bridged interaction with the side chain of Glu215 (Fig. 2D). The in-
duced conformational changes provide 2 with access to the protein
surface creating opportunities for structure-driven compound elabora-
tion. Notably, the recently disclosed structure of fascin in complex with
an unrelated small molecule bound in the same site9 shows fascin
adopting a similar conformation (RMSD < 1.3 Å for 483 Cα atoms).
To identify compounds which could potentially fill these additional
areas a hybrid virtual screen was carried out. The first method was struc-
ture-based: 809 commercial analogues of compound 2 and ≈2.7 million
lead-like molecules from our in-house virtual library were docked13 in the
enclosed site. To prioritize the docked compounds, a multi-parameter op-
timization was performed using Pareto efficiency14 as the ranking technique
with calculated free energy of binding (from docking), QED15 and interac-
tion pattern similarity (based on compound 2 interaction fingerprints)16 as
the parameters to optimize. The second method was ligand-based using
shape-similarity17 to find analogues of compound 2 in our in-house library.
Combining the results, 110 commercial compounds were tested by SPR at a
screening concentration of 100 µM. The resulting binders were validated by
co-crystallization and SPR dose-response experiments. Eighteen compounds
were confirmed to bind in the same site as 2, and three yielded Kd va-
lues < 100 μM. Of these three, we decided to progress the isoquinolinone 3
(SPR Kd=29.3 ± 5.8 µM; Fig. 2A and E), which maintains affinity similar
to 2 despite substituent truncations from both the benzyl and the core ring
system. The pyrazolamide moiety forms an edge-to-face aromatic interac-
tion with the Trp101 side chain. It also moves the bridging water seen in the
fascin·compound 2 complex structure deeper into the binding site. This
water now hydrogen-bonds to the Thr213 side chain, the Leu214 backbone
carbonyl and the ligand amide in addition to the Glu215 side chain, which
‘follows’ it by adopting a different rotamer (Fig. 2D and E). Analysis of this
water with MOE 3D-RISM18 suggests it is relatively tightly bound
(ΔG=−3.9 kJ/mol) and that displacing it would likely be energetically
unfavorable.
In order to measure the effect of these compounds on fascin activity
we developed a robust and highly reproducible in vitro F-actin bundling
assay, based on a previously published method.19 Unlike compound 1,
both 2 and 3 inhibit fascin in this bundling assay. Compound 3 inhibits
actin bundling with an IC50 of 67.9 ± 3.5 μM, giving an approximately
two-fold fall-off from SPR binding affinity. A similar fall-off is seen for
other compounds in this series.
Considering that both 1 and 2 place a substituted phenyl into the
hydrophobic pocket, it seemed plausible that the plain benzyl of 3 is not
optimal for filling the available space. Additionally, given that this in-
duced pocket is likely to show some plasticity, it may be possible to
open it up further by extending the compound. To investigate this, we
synthesized a series of benzyl derivatives of 3 (Table 1). Introduction of
a para-halo substituent (compounds 4 and 5) increased binding affinity
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Fig. 1. Fascin structure and fragment 1 binding. A) Chemical structure of
compound 1. B) Overall structure of fascin represented as a cartoon with the
four β-trefoil domains colored differently and labelled. The bound compound 1
is shown as cyan spheres (PDB id 6I0Z). C) The interface between domains 1
and 2 in apo-fascin (PDB id 3P53)10. Domains are delineated by separate sur-
faces colored as in B) and labelled. Residues at the interface are shown as grey
sticks and labelled with single-letter amino acid codes and residue numbers. D)
Compound 1 bound to fascin, representation and view as in C) with the com-
pound shown as cyan sticks. The structures were superimposed on domain 1
only. E) Detailed view of the binding site shown as a semi-transparent surface
with surrounding protein residues drawn as sticks colored and labelled. Hy-
drogen bonds are shown as dashed pale green lines, other conventions as for D).
(For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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≈14-fold compared to 3. The crystal structure of 5 bound to fascin
shows a binding mode without substantial changes in either ligand or
protein conformation compared to the fascin·3 complex (Fig. S1A). A
single meta-fluoro substituent (6) is equipotent while m-chloro sub-
stitution (7) improved affinity, though less so than 4 or 5. This may be
partly explained by the slight differences in binding mode for meta
substituted compounds compared to 3, in which the benzyl moiety is
rotated to line up the m-substituent with a pocket indentation (Fig.
S1B). In light of this conformational divergence, it is not surprising that
m,p-dihalo compounds exhibit sub-additive affinity gains, though both
8 and 9 showed improved binding over mono- or unsubstituted ana-
logues with SPR Kd values of 1.2 and 1.5 μM respectively. The structure
of the fascin·9 complex shows the compound adopts a conformation
with the phenyl rotated to an intermediate position compared to the
meta and para analogues (Fig. S1C). Larger meta or para substituents
(e.g. 10 and 11; Fig. S1D) are tolerated by expanding the hydrophobic
pocket. However, the associated conformational penalty consistently
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Fig. 2. Fascin undergoes a significant conformational change upon binding of
compounds 2 and 3. A) Chemical structures of 2 and 3. B) Apo-fascin (PDB id 3P53,
red) and the fascin·2 complex (PDB id 6I10, purple) superimposed on the relatively
rigid domains 2–4 (grey; RMSD=1.1Å for 348 Cα atoms), viewed along the do-
main 1 rotation axis. C) Compound 2 bound to fascin oriented as Fig. 1C/D (pro-
teins superimposed on domain 1). D) Detail view of the fascin·2 complex. Conven-
tions as in Fig. 1E, the red sphere represents a bound water molecule. E) Detailed
view of the fascin·3 complex (PDB id 6I11). (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
Table 1
Variation of benzyl substituents.
Compound Kd ± SDa (µM) IC50 ± SDb (µM)
3 29.3 ± 5.8 67.9 ± 3.5
4 2.7 ± 0.1 nd
5 2.7 ± 0.1 4.6 ± 0.3
6 29.2 ± 0.9 nd
7
7.6 ± 2.5 11.4 ± 4.2
8 1.2 ± 0.1 2.1 ± 0.8
9 1.5 ± 0.1 1.3 ± 0.2
10 6.6 ± 2.0 8.6 ± 4.2
12 46 ± 1.7 nd
a Kd: SPR binding affinity, values are mean ± standard deviation from
n=2–10 separate experiments.
b IC50: compound concentration that reduces actin bundling by 50%, values
are mean ± standard deviation.
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makes these compounds less potent. Introduction of an ortho substituent
decreases potency both in combination with a para substituent (12) or
as a single substituent (data not shown). Taken together the SAR sug-
gests that m,p-dichloro substitution (9) is close to optimal in this series.
We next investigated altering the bicyclic scaffold of 3 (Table 2),
taking care to retain the pyridinone moiety, which we found to be es-
sential for binding. Complete deletion of the outer ring (13) led to a
significant loss of affinity, which can be partly recovered with the ad-
dition of a 3-amino substituent (14), which donates an additional hy-
drogen bond to the Phe216 backbone carbonyl. The naphthyridinones
16 and 17 maintain binding affinities similar to the parent iso-
quinolinone, while placement of the naphthyridinone nitrogen next to
the amide (15) results in the formation of an intramolecular hydrogen
bond stabilising a conformation that is not optimal for fascin binding
(Fig. S2A), and thus a decrease in binding affinity. For comparison, a
matched pyrazolopyridinone 19 shows 7-fold weaker binding.
Considering their improved physicochemical properties and che-
mical tractability, we decided to progress a naphthyridinone, initially
by adding substituents to replicate the space filling of the cyclic sul-
phone of 2. A binding mode comparison (Fig. S2B) suggested that
substitution from C5 would provide the best-matched vector, though 6-
substituents should be able to access the same space. Due to concerns
about the potential clash between a 5-substituent and the pyr-
azoloamide preventing the compound from adopting the preferred
fascin-binding conformation, we opted to elaborate 17 through sub-
stitution from the 6-chloro derivative (Table 3). The introduction of
simple alkylamine substituents (20, 22) had no significant effect on
fascin binding. The sulphonamide (21) aiming to more closely replicate
the sulphone of compound 2 also failed to improve affinity. The pi-
perazine 23 gave slightly improved fascin binding, despite ostensibly
placing a partial positive charge close to the guanidine group of Arg217
(cf. Fig. 2E). The piperidine analogue (24) shows further improved
fascin binding and inhibition. The crystal structure of the fas-
cin·compound 24 complex shows the compound binding broadly as
expected (Fig. S3A and B). The naphthyridinone makes an additional
water-bridged interaction with the Phe216 backbone carbonyl. The
piperidine orients to fill the space between Ala58 and Arg217 (Fig.
S3C), but does not make any specific interactions, as its amine points
towards bulk solvent. Comparing the binding modes of 24 and 9 reveals
that the core ring system of 24 is rotated slightly (Fig. S3D), possibly to
optimize the fit of the piperidine. This small rotation has an amplified
effect on the position of the pyrazoloamide, bringing the pyrazole closer
to Trp101 and Arg225 while at the same time improving the hydrogen
bond from the amide to the bridging water. The displacement observed
for 24 suggests that naphthyridinones with bulky 6-substituents may be
Table 2
Variation of the bicyclic scaffold.
Compound Kd ± SDa (µM) IC50 ± SDb
(µM)
9 1.5 ± 1 1.3 ± 0.2
13 >100 nd
14 21 ± 4.2 > 100
15 >100 nd
16 1.6 ± 0.1 5.3 ± 0.8
17 1.3 ± 0.1 3.8 ± 0.3
18 >100 nd
19 10.0 ± 1.4 10.4 ± 0.2
X, R=Me; Y, R= 3-pyrolidine;
a Kd: SPR binding affinity, values are mean ± standard deviation from
n=2–10 separate experiments;
b IC50: compound concentration that reduces actin bundling by 50%, values
are mean ± standard deviation from n=2–4 separate experiments; nd: not
determined.
Table 3
6-substitution of the napthyridinone core.
Compound Kd ± SDa (µM) IC50 ± SDb (µM)
17 H 1.3 ± 0.1 3.8 ± 0.3
20 1.1 ± 0.2 nd
21 2.0 ± 0.1 nd
22 1.03 ± 0.03 nd
23 0.58 ± 0.02 0.63 ± 0.09
24 0.25 ± 0.1 0.51 ± 0.07
a Kd: SPR binding affinity, values are mean ± standard deviation from
n=2–10 separate experiments;
b IC50: compound concentration that reduces actin bundling by 50%, values
are mean ± standard deviation from n=2–4 separate experiments; nd: not
determined.
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sterically restricted from adopting an optimal core binding mode. In
light of this we chose to revisit the pyrazolo series, where we had
previously observed that the equally bulky cyclic sulphone substituent
of 2 was compatible with the ‘standard’ core orientation (Fig. S2B). The
truncated compound 25 showed diminished binding (Table 4),
revealing that addition of either the pyrazoloamide in the 7-position (to
obtain 19) or the cyclic sulphone at N1 (to obtain 2) to this compound
improves fascin affinity> 50-fold and 23-fold, respectively. Combining
these key features into one compound gave 26, with an SPR Kd of
0.6 μM, suggesting near-additive gains in binding affinity compared to
24 and almost closing the potency gap to our best naphthyridinones.
We next investigated changes to the heteroaromatic amide. In line
with the predicted importance of the bridging water discussed above,
any changes to the amide (N-alkylation, carbonyl deletion) abolish
fascin binding (not shown). On the other hand, the methylpyrazole
interacts with the protein through stacking with the indole of Trp101. A
number of compounds with alternative heterocycles were made to
probe this interaction, focusing on five- and six-membered nitrogen-
containing heterocycles. Of these the pyridin-4-yl 27 yielded the lar-
gest, albeit still modest, improvement over 26 in terms of both affinity
and inhibition. QM calculations (Fig. S4) suggest that at least for
(hetero)aryl derivatives improved stacking with Trp101 may be a major
factor in this increase in potency.
Given the success of 24 and to alleviate concerns about chemical
stability of the cyclic sulphone substituent, we opted to replace it with a
1-piperidin-4-yl.
Synthesis of this was achieved starting from the commercially
available diethyl beta-ketoglutarate (29) and reacting with N,N-di-
methylformamide dimethyl acetal (Scheme 1).20 Addition of tert-butyl
4-hydrazinopiperidine-1-carboxylate led to the pyrazole (31), which
was further functionalised by refluxing with Bredereck’s reagent fol-
lowed by the addition of dichlorobenzylamine. Partial cyclisation was
observed at this stage, however, the crude product was fully cyclised
with sodium ethoxide. This gave intermediate pyrazlopyridinone (32)
in good yield over the three steps. Saponifaction of the ester, coupling
of the 4-amino pyridyl and removal of the Boc protecting group furn-
ished BDP-13176 (28). BDP-13176 further improved fascin affinity,
giving us the best fascin binder (SPR Kd= 85 ± 0.02 nM, LE=0.29,
ITC Kd= 50 nM; Fig. 3A and B) and actin bundling inhibitor
(IC50= 240 ± 0.01 nM; Fig. 3C and D).
The crystal structure of fascin in complex with BDP-13176 shows
the compound adopting the expected overall binding mode (Fig. 4), but
with a slight core rotation in the opposite direction from that observed
for 24 (Fig. S5). The compound‘s in vitro physicochemical and DMPK
properties (Table S1) are within acceptable limits with low lipophilicity
(LogD7.4= 1.8) and reasonable kinetic solubility (midpoint= 65 µM).
The compound was also moderately stable in both human and mouse
Table 4
Further substitutions of the pyrazolopyridinone scaffold.
Compound R1-group R2-group Kd ± SDa (µM) IC50 ± SDb (µM)
25 N H >500 nd
2 N 29.5 ± 8.3 67.6 ± 2.4
26 0.60 ± 0.05 0.63 ± 0.15
27 0.27 ± 0.04 0.33 ± 0.06
28 0.09 ± 0.02 0.24 ± 0.01
a Kd: SPR binding affinity, values are mean ± standard deviation from
n=2–10 separate experiments.
b IC50: compound concentration that reduces actin bundling by 50%, values
are mean ± standard deviation from n=2–4 separate experiments; nd: not
determined.
Scheme 1. Reagents and conditions: (a) N, N-di-
methylformamide dimethyl acetal, ethanol r.t,
(75%); (b) 4 tert-butyl 4-hydrazinopiperidine-1-
carboxylate, ethanol, reflux., (27%); (c-e)
Bredereck’s, toluene reflux; 3,4-dichlorophenyl)
methanamine, acetic acid, toluene; sodium eth-
oxide, ethanol (3 steps 85%) (f) Sodium hydroxide,
ethanol r.t. (84%),(g) HATU, N,N-diisopropylethy-
lamine, DMF, r.t., (83%), (h) TFA, DCM r.t. (52%).
S. Francis, et al. Bioorganic & Medicinal Chemistry Letters xxx (xxxx) xxx–xxx
5
liver microsomes (Human Clint= 6.4, Mouse Clint = 11.8, µL/min/mg
protein). However, the compound has low Caco-2 permeability (A-B
Papp= 0.15x10-6 cm/s) and high efflux (efflux ratio= 37.8).
In conclusion, fragment screening coupled with crystallography and
computational approaches allowed identification of a cryptic pocket
within fascin. Using compound 2 (Kd= 29.5 ± 8.3 µM)12 as a starting
point combined with virtual screening and structure-based design al-
lowed us to develop potent and functionally active fascin binders.
Crystal structures reveal the compounds bind with a hydrophobic
‘hook’ in an induced pocket between the first two β-trefoil domains of
fascin and from there extend towards the protein surface, effecting a
substantial conformational change in domain 1. While the mechanism
by which our compounds inhibit bundling remains unclear, it is worth
noting that fascin’s two major proposed actin binding regions involve
domain 1 and cross a domain boundary. The ligand-induced con-
formational change would deform both these regions and thereby dis-
rupt actin binding (Fig. S6). We anticipate these compounds to be a
useful foundation to further probe fascin’s potential role in tumor in-
vasion and metastasis.
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Fig. 3. Comparison of SPR binding affinity, ITC binding parameters and functional bundling assay potency for BDP-13176. A) Multi-cycle kinetic curve for BDP-
13176 binding to immobilised (His8)2-fascin. Data were fitted using a 1:1 kinetic binding model. B) ITC titration thermogram and referenced isotherm (first point
removed) of BDP-13176 (150 µM in syringe) binding to fascin (15 µM in cell). Fitting of the isotherm to a 1:1 binding model resulted in the following binding
parameters: N=1.05 ± 0.01, Kd= (45 ± 7) nM, ΔH=(−2400 ± 200) cal mol−1, ΔS=−45.9 cal mol−1 K−1. C) Inhibition of fascin bundling activity by BDP-
13176. Inhibition of bundling activity can be seen as fascin and F-actin move from the pellet (P) to the supernatant (S) with increasing concentrations of BDP-13176.
D) Concentration-response curve for bundling assay data shown in C).
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Fig. 4. Binding of BDP-13176 to fascin. A) Crystal structure of the fascin·BDP-
13176 complex (PDB id 6I18). The bridging water seen in earlier complexes is
replaced by two ordered waters that together make the same contacts as the
single bound water. B) Interaction plot for BDP-13176 bound to fascin.
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